Validations Queue
108,318 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 9 of 22, 200 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
108,318
Reviewed
13
Filtered
4,344
page 9 / 22
Showing on page
200
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.59 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA211020: BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE) — GRAVITI PHARMS | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208175: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (PHENTERMINE HYDROCHLORIDE) — DR REDDYS LABS SA | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA218096: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — APOTEX | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA BLA761063: EMGALITY (GALCANEZUMAB-GNLM) — ELI LILLY AND CO | fda 2026-06-05 | 235_031 Eli Lilly perilously close to $1 trillion market cap at ~$950B. Alex Wissner-Gross | Markets/Stocks | 39% | |
| 0.59 | FDA ANDA219370: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUSON | fda 2026-06-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA218821: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — CONCORD BIOTECH LTD | fda 2026-06-09 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.59 | FDA ANDA201972: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — AUROLIFE PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA203447: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ANI PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040331: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA201278: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — RHODES PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA077723: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — STRIDES PHARMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA218754: APREPITANT (APREPITANT) — AZURITY | fda 2026-06-16 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA202677: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — ALVOGEN | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA076636: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ACTAVIS ELIZABETH | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA019892: DILAUDID (HYDROMORPHONE HYDROCHLORIDE) — RHODES PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA087463: OXYCET (ACETAMINOPHEN) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA213414: DAPSONE (DAPSONE) — ALEMBIC | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA020622: COPAXONE (GLATIRAMER ACETATE) — TEVA PHARMS USA | fda 2026-06-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA202160: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — AUROLIFE PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA217737: IOHEXOL (IOHEXOL) — AMNEAL | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA075982: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — PLIVA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040777: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA079099: LAMOTRIGINE (LAMOTRIGINE) — GLENMARK PHARMS LTD | fda 2026-04-17 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA091427: PAROXETINE HYDROCHLORIDE (PAROXETINE HYDROCHLORIDE) — AUROBINDO PHARMA USA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA079162: TOPIRAMATE (TOPIRAMATE) — INVAGEN PHARMS | fda 2026-04-24 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA078257: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — ONESOURCE SPECIALTY | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761235: VABYSMO (FARICIMAB-SVOA) — GENENTECH INC | fda 2026-04-09 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA021880: REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBB | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA220493: BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE) — ANTHEA PHARMA | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA091655: ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE) — MICRO LABS | fda 2026-04-22 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA216992: DEFLAZACORT (DEFLAZACORT) — UPSHER SMITH LABS | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA220328: FLUVOXAMINE MALEATE (FLUVOXAMINE MALEATE) — APPCO | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA204982: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (PHENTERMINE HYDROCHLORIDE) — ACTAVIS LABS FL INC | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA218364: LEVETIRACETAM IN SODIUM CHLORIDE (LEVETIRACETAM) — MYLAN LABS LTD | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA076228: RISPERIDONE (RISPERIDONE) — HERITAGE PHARMA AVET | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA761070: FASENRA (BENRALIZUMAB) — ASTRAZENECA AB | fda 2026-05-13 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA BLA761452: IMMGOLIS (GOLIMUMAB-SLDI) — ACCORD BIOPHARMA INC. | fda 2026-05-15 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA220711: BEQALZI (SONROTOCLAX) — BEONE MEDICINES USA | fda 2026-05-13 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA219423: WIDAPLIK (AMLODIPINE BESYLATE) — AZURITY | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA217379: CAVHANZA (NILOTINIB) — FLEX PHARMA | fda 2026-05-29 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.59 | FDA BLA761309: COLUMVI (GLOFITAMAB-GXBM) — GENENTECH INC | fda 2026-06-22 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA NDA021529: IMPLANON (ETONOGESTREL) — ORGANON | fda 2026-05-28 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA211187: MACITENTAN (MACITENTAN) — TEVA PHARMS USA INC | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA200296: RISEDRONATE SODIUM (RISEDRONATE SODIUM) — AUROBINDO PHARMA LTD | fda 2026-06-08 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA219530: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — MACLEODS PHARMS LTD | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA212990: LABETALOL HYDROCHLORIDE (LABETALOL HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA064050: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — PADAGIS US | fda 2026-06-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA219830: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — ORIENT PHARMA | fda 2026-06-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA206321: SAXENDA (LIRAGLUTIDE) — NOVO | fda 2026-06-02 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA203863: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — EPIC PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA201194: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — VISTAPHARM LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA204575: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — AUROLIFE PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA077712: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — STRIDES PHARMA INTL | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA210644: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — ABHAI LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA213906: LEVORPHANOL TARTRATE (LEVORPHANOL TARTRATE) — SUN PHARM INDS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA213155: LIRAGLUTIDE (LIRAGLUTIDE) — MYLAN INSTITUTIONAL | fda 2026-06-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA212436: IBRANCE (PALBOCICLIB) — PFIZER | fda 2026-06-24 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA210732: LEVOMILNACIPRAN HYDROCHLORIDE (LEVOMILNACIPRAN HYDROCHLORIDE) — HIKMA | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA212414: LENALIDOMIDE (LENALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA219293: DANZITEN (NILOTINIB TARTRATE) — AZURITY | fda 2026-04-14 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA220264: VERICIGUAT (VERICIGUAT) — CHANGZHOU PHARMACEUTICAL FACTORY | fda 2026-04-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA211559: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MACLEODS PHARMS LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA211579: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — LUPIN | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA217180: JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORPORATION | fda 2026-05-01 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA BLA761349: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.59 | FDA ANDA212336: ANDA212336 ((unspecified)) — DR REDDYS LABS LTD | fda 2026-05-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA216537: CARBIDOPA AND LEVODOPA (CARBIDOPA) — AUROBINDO PHARMA LTD | fda 2026-05-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA761449: TYENNE (TOCILIZUMAB-AAZG) — FRESENIUS KABI USA | fda 2026-05-20 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA211026: MACITENTAN (MACITENTAN) — SEASONS BIOTECH | fda 2026-05-19 | INF_039 Consumer-facing AI hardware shortages will worsen: high-Unified-Memory Apple Mac Studio lead times now range 6 days to 6 weeks (up to ~54 days) because data centers are absorbing the world's HBM and memory supply — DRAM market transitioning to hourly v... Alex Finn | Consumer | 77% | |
| 0.59 | FDA ANDA217758: AMMONIUM LACTATE (AMMONIUM LACTATE) — ZYDUS LIFESCIENCES | fda 2026-05-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA022561: MAVENCLAD (CLADRIBINE) — EMD SERONO INC | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA022472: AFREZZA (INSULIN RECOMBINANT HUMAN) — MANNKIND | fda 2026-05-29 | 245_027 Colossal DNA synthesis delivery will reach 20x the largest prior delivery by end of 2026 Ben Lamm | Biotech/Longevity | 41% | |
| 0.59 | FDA BLA761069: IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD | fda 2026-05-28 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA070311: DIAZEPAM (DIAZEPAM) — HIKMA | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761061: TREMFYA (GUSELKUMAB) — JANSSEN BIOTECH | fda 2026-05-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA209633: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — BRECKENRIDGE | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA BLA761089: AJOVY (FREMANEZUMAB-VFRM) — TEVA PHARMS USA | fda 2026-06-05 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA050671: VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER (VANCOMYCIN HYDROCHLORIDE) — BAXTER HLTHCARE | fda 2026-06-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA212374: EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — AUROBINDO PHARMA LIMITED | fda 2026-06-11 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA206321: SAXENDA (LIRAGLUTIDE) — NOVO | fda 2026-06-02 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA215230: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (BRIMONIDINE TARTRATE) — ALEMBIC | fda 2026-06-11 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA209738: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — MICRO LABS | fda 2026-06-03 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA077494: RISPERIDONE (RISPERIDONE) — PH HEALTH | fda 2026-06-08 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA208434: ALECENSA (ALECTINIB HYDROCHLORIDE) — HOFFMANN-LA ROCHE | fda 2026-06-11 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA BLA761262: SKYRIZI (RISANKIZUMAB-RZAA) — ABBVIE INC | fda 2026-06-26 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA203823: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — LANNETT CO INC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA204246: FYREMADEL (GANIRELIX ACETATE) — SUN PHARM | fda 2026-06-16 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA202537: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — VISTAPHARM LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA214378: TAPENTADOL HYDROCHLORIDE (TAPENTADOL HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA211748: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ALKEM LABS LTD | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA209021: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ASCENT PHARMS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA021011: ROXICODONE (OXYCODONE HYDROCHLORIDE) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA207418: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ASCENT PHARMS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA202116: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ALVOGEN | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040545: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA022555: CYSVIEW KIT (HEXAMINOLEVULINATE HYDROCHLORIDE) — PHOTOCURE ASA | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA091633: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — SUN PHARM INDS INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA074597: HYDROMORPHONE HYDROCHLORIDE (HYDROMORPHONE HYDROCHLORIDE) — HIKMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208269: HYDROCODONE BITARTRATE (HYDROCODONE BITARTRATE) — ALVOGEN | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA212773: IMATINIB MESYLATE (IMATINIB MESYLATE) — EUGIA PHARMA | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA078582: LEVETIRACETAM (LEVETIRACETAM) — STRIDES PHARMA | fda 2026-04-21 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA215243: RAMELTEON (RAMELTEON) — MICRO LABS | fda 2026-06-04 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA NDA020310: NIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — KRAMER | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761451: SAPHNELO (ANIFROLIMAB-FNIA) — ASTRAZENECA AB | fda 2026-04-24 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA090348: ZIPRASIDONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) — CHARTWELL RX | fda 2026-04-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA074544: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — EPIC PHARMA LLC | fda 2026-05-05 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA075327: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — ANI PHARMS | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761352: BIZENGRI (ZENOCUTUZUMAB-ZBCO) — MERUS N.V. | fda 2026-05-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA BLA761304: VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — ARGENX BV | fda 2026-05-08 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA077615: DIVALPROEX SODIUM (DIVALPROEX SODIUM) — APOTEX | fda 2026-05-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA208433: LINAGLIPTIN (LINAGLIPTIN) — TEVA PHARMS USA | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA219622: TRIMBOW (BECLOMETHASONE DIPROPIONATE) — CHIESI | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA217604: PYRIDOSTIGMINE BROMIDE (PYRIDOSTIGMINE BROMIDE) — AMNEAL | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA217186: CREXONT (CARBIDOPA) — IMPAX | fda 2026-05-15 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.59 | FDA ANDA211417: LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM) — MACLEODS PHARMS LTD | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA220104: MIRTAZAPINE (MIRTAZAPINE) — MICRO LABS | fda 2026-05-19 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA BLA022472: AFREZZA (INSULIN RECOMBINANT HUMAN) — MANNKIND | fda 2026-05-29 | 245_031 99% of synthetic biology focus will remain on human healthcare; similar tech applies more broadly Ben Lamm | Biotech/Longevity | 41% | |
| 0.59 | FDA NDA050574: SANDIMMUNE (CYCLOSPORINE) — NOVARTIS | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA209803: STEGLATRO (ERTUGLIFLOZIN) — MSD SUB MERCK | fda 2026-06-03 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTD | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA021529: IMPLANON (ETONOGESTREL) — ORGANON | fda 2026-05-28 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA220866: ANDA220866 ((unspecified)) — HETERO LABS LIMITED | fda 2026-06-01 | COD_TECH_001 A16/N2-class TSMC process availability materially supports 2027 AI accelerator ramps Codex Research Pack | Semis | 50% | |
| 0.59 | FDA ANDA220866: ANDA220866 ((unspecified)) — HETERO LABS LIMITED | fda 2026-06-01 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA207961: DABIGATRAN ETEXILATE MESYLATE (DABIGATRAN ETEXILATE MESYLATE) — HETERO LABS LTD III | fda 2026-06-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA209829: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — ZYDUS PHARMS | fda 2026-06-05 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA209829: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — ZYDUS PHARMS | fda 2026-06-05 | SEM_026 Nvidia's next 'Rubin' product cycle is the most critical factor for semi industry in coming year — further integrates logic + HBM. Joseph Moore | Semis/Products | 62% | |
| 0.59 | FDA ANDA209738: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — MICRO LABS | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA203823: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — LANNETT CO INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA204979: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ANI PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208305: METHADONE HYDROCHLORIDE (METHADONE HYDROCHLORIDE) — SUN PHARM INDUSTRIES | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA209624: BOSUTINIB (BOSUTINIB MONOHYDRATE) — MSN | fda 2026-06-12 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA077454: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — ANI PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA077454: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — ANI PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA040545: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SPECGX LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040910: OXYCODONE AND ASPIRIN (ASPIRIN) — EPIC PHARMA LLC | fda 2026-06-18 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA NDA220073: ELIQUIS (APIXABAN) — BRISTOL | fda 2026-06-24 | SEM_029 Blackwell RTX PRO 5000 (72GB) engineered with 50% memory boost over previous generation — deliberate architectural concession for larger AI training. Nvidia | Semis/Products | 79% | |
| 0.59 | FDA BLA761263: LUNSUMIO VELO (MOSUNETUZUMAB-AXGB) — GENENTECH INC | fda 2026-06-18 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA ANDA210347: PIROXICAM (PIROXICAM) — STRIDES PHARMA | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040778: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS NY | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA202426: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE) — APOTEX | fda 2026-04-30 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA204687: VALSARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — SCIEGEN PHARMS | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA090124: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — AUROBINDO PHARMA | fda 2026-04-15 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA214398: LENALIDOMIDE (LENALIDOMIDE) — LUPIN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA220274: SODIUM ACETATE (SODIUM ACETATE) — EXTROVIS | fda 2026-04-17 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA203364: MESNA (MESNA) — RISING | fda 2026-04-09 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA218441: SITAGLIPTIN (SITAGLIPTIN) — BIOCON PHARMA LTD | fda 2026-05-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA218316: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-06-18 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA078945: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ONDANSETRON HYDROCHLORIDE) — AVET LIFESCIENCES | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA022433: BRILINTA (TICAGRELOR) — ASTRAZENECA | fda 2026-05-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA016730: DEXTROSE 5% IN PLASTIC CONTAINER (DEXTROSE) — B BRAUN | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA076228: RISPERIDONE (RISPERIDONE) — HERITAGE PHARMA AVET | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA220078: VORICONAZOLE (VORICONAZOLE) — ZHEJIANG NOVUS | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA219189: GALLIUM GA-68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) — IONETIX | fda 2026-05-14 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA BLA103792: HERCEPTIN (TRASTUZUMAB) — GENENTECH | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA077615: DIVALPROEX SODIUM (DIVALPROEX SODIUM) — APOTEX | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761106: HERCEPTIN HYLECTA (TRASTUZUMAB AND HYALURONIDASE-OYSK) — GENENTECH INC | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA216453: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ELITE LABS INC | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA217552: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ALEMBIC | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761354: TOFIDENCE (TOCILIZUMAB-BAVI) — BIOGEN MA | fda 2026-05-22 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA BLA125166: SOLIRIS (ECULIZUMAB) — ALEXION PHARM | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA217379: CAVHANZA (NILOTINIB) — FLEX PHARMA | fda 2026-05-29 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA BLA761306: EBGLYSS (LEBRIKIZUMAB-LBKZ) — ELI LILLY AND CO | fda 2026-06-09 | 235_031 Eli Lilly perilously close to $1 trillion market cap at ~$950B. Alex Wissner-Gross | Markets/Stocks | 39% | |
| 0.59 | FDA NDA218784: VORANIGO (VORASIDENIB) — SERVIER | fda 2026-06-10 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA218821: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — CONCORD BIOTECH LTD | fda 2026-06-09 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA214378: TAPENTADOL HYDROCHLORIDE (TAPENTADOL HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-18 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA207510: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — WES PHARMA INC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA207511: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — HIBROW HLTHCARE | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA207932: BELBUCA (BUPRENORPHINE HYDROCHLORIDE) — BDSI | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA020883: ARGATROBAN (ARGATROBAN) — SANDOZ | fda 2026-06-16 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208708: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — RUBICON RESEARCH | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA202662: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA217042: RIFAPENTINE (RIFAPENTINE) — MACLEODS PHARMS LTD | fda 2026-06-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA220436: NAVITRUX (FOSAPREPITANT) — AVYXA HOLDINGS | fda 2026-06-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA210347: PIROXICAM (PIROXICAM) — STRIDES PHARMA | fda 2026-06-25 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA203638: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — AMNEAL PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA761530: LUMVOA (VELIGROTUG-VVZE) — VIRIDIAN THERAPEUTICS INC | fda 2026-06-26 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA217281: LENALIDOMIDE (LENALIDOMIDE) — NOVUGEN | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA206252: QUETIAPINE FUMARATE (QUETIAPINE FUMARATE) — ACCORD HLTHCARE | fda 2026-04-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA210672: MULTIPLE VITAMINS INJECTION ADULT (ALPHA-TOCOPHEROL ACETATE) — APOTEX | fda 2026-04-09 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.59 | FDA NDA021121: CONCERTA (METHYLPHENIDATE HYDROCHLORIDE) — JANSSEN PHARMS | fda 2026-04-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA078582: LEVETIRACETAM (LEVETIRACETAM) — STRIDES PHARMA | fda 2026-04-21 | 247_041 AI-powered drugs have 85% phase 1 success vs 52% traditional Peter Diamandis | Biotech/Longevity | 55% | |
| 0.59 | FDA BLA125504: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA220660: ELTROMBOPAG OLAMINE (ELTROMBOPAG OLAMINE) — AIZANT | fda 2026-04-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | fda 2026-04-16 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA NDA020785: THALOMID (THALIDOMIDE) — BRISTOL-MYERS | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA217239: TORSEMIDE (TORSEMIDE) — MICRO LABS | fda 2026-05-01 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA213929: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — LEADING | fda 2026-05-05 | 245_027 Colossal DNA synthesis delivery will reach 20x the largest prior delivery by end of 2026 Ben Lamm | Biotech/Longevity | 41% | |
| 0.59 | FDA NDA212306: XPOVIO (SELINEXOR) — KARYOPHARM THERAPS | fda 2026-04-30 | 235_038 David Sinclair begins partial epigenetic reprogramming trials with Life Biosciences in March 2026. Peter Diamandis | Biotech/Longevity | 74% | |
| 0.59 | FDA NDA021303: ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — TAKEDA PHARMS USA | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA206829: ZERBAXA (CEFTOLOZANE SULFATE) — CUBIST PHARMS LLC | fda 2026-05-12 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA219189: GALLIUM GA-68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) — IONETIX | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA219722: L-GLUTAMINE (L-GLUTAMINE) — ANNORA PHARMA | fda 2026-05-26 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA091404: MEROPENEM (MEROPENEM) — ACS DOBFAR | fda 2026-05-20 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% |